A forum for researchers, students and applicants in the field of cyclodextrin technology
This multicentre, randomised, double-blind, positive-controlled, noninferiority phase III clinical trial aimed to investigate the efficacy and safety of adamagammadex compared
Sugammadex is a novel selective relaxant binding agent for aminosteroid neuromuscular blocking agents (NMBAs). However, existing literature reveals major knowledge
Sugammadex (SGM) is the first cyclodextrin derivative approved as an API, the result of a rational drug design, with a
Zhao et al. reported on a phase IIa, single-center, randomized, open-label, and dose-finding study that enrolled 35 patients under general
This work was aimed at enhancing butamben (BTB) anesthetic efficacy by the “drug-in cyclodextrin (CD)-in deformable liposomes” strategy. In the
A recently posted phase 2 clinical trial (not yet recruiting) aims to evaluate the effect of ADV6209, a new oral
